Results and implications of using a new eq-5d value set for cost-utility analyses in sweden. An application using enzalutamide (xtandi®) verse best supportive care for treatment of metastatic castration resistant prostate cancer (MCRPC).

Value Health

Quintiles Consulting, Barcelona, Spain.

Published: November 2014

Download full-text PDF	Source
http://dx.doi.org/10.1016/j.jval.2014.08.2350	DOI Listing

Publication Analysis

implications eq-5d

eq-5d set

set cost-utility

cost-utility analyses

analyses sweden

sweden application

application enzalutamide

enzalutamide xtandi®

xtandi® verse

verse best

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!